DR. JEFFREY HOLT, DDS
Dentist at Grant St, Denver, CO
License number
Colorado 00202727
Category
Dentist
Type
General Practice
Address
Address
9760 Grant St STE 100, Denver, CO 80229
Phone
(720) 583-1425
Personal information
See more information about JEFFREY HOLT at radaris.comName
Address
Phone
2915 Orchard Ave, Grand Junction, CO 81504
5305 Tabor St, Arvada, CO 80002
Professional information
See more information about JEFFREY HOLT at trustoria.com
Dr. Jeffrey Holt, Aurora CO - MD (Doctor of Medicine)
Dr. Jeffrey Holt, Aurora CO - MD (Doctor of Medicine)
Specialties:
Anatomic & Clinical Pathology
Address:
12605 E 16Th Ave, Aurora 80045
(720) 848-0000 (Phone)
UNIVERSITY OF COLORADO AT DENVER
12631 E 17Th Ave, Aurora 80045
(720) 848-0000 (Phone), (303) 724-3712 (Fax)
(720) 848-0000 (Phone)
UNIVERSITY OF COLORADO AT DENVER
12631 E 17Th Ave, Aurora 80045
(720) 848-0000 (Phone), (303) 724-3712 (Fax)
Certifications:
Anatomic & Clinical Pathology, 1983
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
University of Mi Med Sch
Graduated: 1979
U Rochester
National Institutes Of Health Clinical Center
University of Mi Med Sch
Graduated: 1979
U Rochester
National Institutes Of Health Clinical Center
Jeffrey T Holt, Aurora CO
Jeffrey T Holt, Aurora CO
Specialties:
Pathologist
Address:
13611 E Colfax Ave, Aurora, CO 80045
Education:
University of Michigan, Medical School - Doctor of Medicine
Strong Memorial Hospital - Residency - Pathology
Strong Memorial Hospital - Residency - Pathology
Board certifications:
American Board of Pathology Certification in Clinical Pathology (Pathology)
Compositions And Methods For Tissue-Based Protein Truncation Test For Disease Diagnosis
Compositions And Methods For Tissue-Based Protein Truncation Test For Disease Diagnosis
US Patent:
2010003, Feb 11, 2010
Filed:
Sep 25, 2007
Appl. No.:
12/442771
Inventors:
Jeffrey T. Holt - Aurora CO, US
International Classification:
G01N 33/574, G01N 33/53, C07K 16/00
US Classification:
435 723, 435 721, 5303871
Abstract:
Embodiments herein concern methods and compositions for diagnosing or predicting the onset of a genetic disorder In certain embodiments, the methods may include use of a rapid and inexpensive assay. In other embodiments, the assay utilizes a tissue sample from a subject to identify the state of a target protein known to associate with a genetic disorder In accordance with these embodiments, the target protein may have a DNA sequence change such as a mutation, deletion, insertion or substitution leading to generation of a termination codon and truncation of the protein. In some embodiments, a composition of an antibody directed to bind a protein associated with a disorder may be used to predict onset of the disorder or predict sensitivity of the disorder to therapeutic treatments.
Systems Test At Lockheed Martin Space Systems Company
Systems Test At Lockheed Martin Space Systems Company
Position:
Systems Test at Lockheed Martin Space Systems Company
Location:
Greater Denver Area
Industry:
Defense & Space
Work:
Lockheed Martin Space Systems Company
-
Systems Test
Compositions, Methods And Uses For Modulation Of Brca 1
Compositions, Methods And Uses For Modulation Of Brca 1
US Patent:
2012004, Feb 16, 2012
Filed:
Apr 13, 2009
Appl. No.:
12/937217
Inventors:
Jeffrey Thomas Holt - Aurora CO, US
Steve Anderson - Denver CO, US
Andrew Cook Nelson - St. Paul CO, US
Steve Anderson - Denver CO, US
Andrew Cook Nelson - St. Paul CO, US
Assignee:
THE REGENTS OF THE UNIVERSITY OF COLORADO - Denver CO
International Classification:
A61K 38/17, A61K 38/30, A61P 35/00, A61K 31/404, A61K 31/663, C07K 16/18, A61K 38/28
US Classification:
514 59, 5303879, 514 86, 514 193, 514414, 514102, 514 194, 514 195
Abstract:
Embodiments of the present invention generally relate to methods, compositions and uses for diagnosis and treatment of cancer. Certain embodiments report methods and compositions for diagnosing and/or treating a subject having a BRCA1-related cancer or sporadic cancer. Some embodiments disclose treatments that can include, but are not limited to, modulation of BRCA1. In some embodiments, methods for identifying a subject with unstable BRCA1 protein are reported.